Philip Scheltens, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, speaks at the Alzheimer’s Research UK (ARUK) Conference 2019, held in Harrogate, UK. He discusses the heterogeneity of Alzheimer’s disease and how this may impact drug trials.